Larimar Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Larimar Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-282.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 92% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-102.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+56%Cash, after subtracting all debt, equals 56% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Larimar Therapeutics, Inc. made a loss over the last year. Larimar Therapeutics, Inc. owes $0.23 for every $1 it owns. Larimar Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLarimar Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.85The share price is 1.85 times Larimar Therapeutics, Inc.'s book value per share, lower than 61% of Healthcare companies in United States.
Market cap
$236 MThe total market value of all of Larimar Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$127 MWhat Larimar Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.23Net worth divided by the number of shares. The share price of $2.27 is 1.9 times this, which is the P/B above.
Return on equity (ROE)
-139.6%Larimar Therapeutics, Inc. lost 139.6% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
Owes vs Owns
0.23×Larimar Therapeutics, Inc. owes $0.23 for every $1 it owns (low), lower than 69% of Healthcare companies in United States.
Dividend yield
NoneLarimar Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossLarimar Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashLarimar Therapeutics, Inc. held $133 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Larimar Therapeutics, Inc.: $236 M ÷ $127 M (30 Jun 2026) = 1.9.
What is Larimar Therapeutics, Inc.'s return on equity?
Larimar Therapeutics, Inc. lost 139.6% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
How much does Larimar Therapeutics, Inc. owe compared with what it owns?
Larimar Therapeutics, Inc. owes $0.23 for every $1 it owns (low), lower than 69% of Healthcare companies in United States.
Does Larimar Therapeutics, Inc. pay a dividend?
No. Larimar Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.